Sulfadoxine
Sulfanilamides
Pyrimethamine
Dihydropteroate Synthase
Antimalarials
Drug Combinations
Chloroquine
Drug Resistance
Plasmodium falciparum
Malaria, Falciparum
Tetrahydrofolate Dehydrogenase
Mefloquine
Dapsone
Proguanil
Congo
Malaria
Sesquiterpenes
Folic Acid Antagonists
Artemisinins
4-Aminobenzoic Acid
Parasitic Sensitivity Tests
Drug Therapy, Combination
Parasitemia
Plasmodium vivax
Drug Evaluation
Kenya
Quinolines
Tanzania
RNA, Protozoan
Treatment Failure
Drug Resistance, Microbial
Point Mutation
Mutation
Alleles
Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. (1/702)
OBJECTIVES: To examine in pregnant women the relationship between HIV infection and malaria prevalence and to determine, in relation to HIV infection, the effectiveness of sulphadoxine-pyrimethamine in clearing P. falciparum infection. METHOD: Descriptive cross-sectional analysis of P. falciparum prevalence in pregnant women at first antenatal visit and of women at delivery who had received two sulphadoxine-pyrimethamine treatments for malaria. HIV status was assessed in 621 women who attended for antenatal care and for delivery at two rural hospitals in southern Malawi in 1993-94. Information was collected on maternal age, parity and gestational age. Prevalence of P. falciparum was measured at first antenatal visit and delivery. Women were given two routine treatment doses of sulphadoxine-pyrimethamine (SP), at first antenatal visit and between 28 and 34 weeks gestation, conforming to Malawi government policy on antimalarial control during pregnancy. RESULTS: Prevalence of HIV infection was 25.6% and all infections were HIV type-1. In primigravidae malaria prevalence at recruitment was 56.3% in HIV-infected and 36.5% in HIV-uninfected women (P=0.04). The corresponding figures for multigravidae were 23.8% and 11.0%, respectively (P<0.01). HIV-infected primigravidae had increased malaria prevalence at all gestational ages. Peak parasite prevalence occurred earlier in gestation in HIV-infected primigravidae (16-19 weeks if HIV-infected; 20-23 weeks if HIV-uninfected). The relative risk for parasitaemia in HIV-infected compared to HIV-uninfected women was significantly increased in three of five parity groups, including the two highest ones (parity>3), indicating parity-specific immunity to malaria was impaired. Malaria prevalence at delivery remained high in HIV-infected women despite prior routine treatment with sulphadoxine-pyrimethamine in pregnancy There was no significant difference in parasite prevalence at delivery between women who did or did not use sulphadoxine-pyrimethamine. CONCLUSIONS: HIV infection is associated with a significant increase in malaria prevalence in pregnant women of all parities with the effect apparent from early in gestation. Two treatment doses of sulphadoxine-pyrimethamine were inadequate to clear parasitaemia in many women by the time of delivery and this occurred independently of HIV status and despite high sensitivity to SP in this area. There is a need to undertake longitudinal studies to determine the incidence of P. falciparum infection in HIV-infected and uninfected pregnant women and to reassess the frequency and timing of sulphadoxine-pyrimethamine treatment doses in these women. Late pregnancy re-infections with P. falciparum probably explain the high parasite prevalence at delivery following sulphadoxine-pyrimethamine treatment at 28-34 weeks gestation. (+info)Response of falciparum malaria to different antimalarials in Myanmar. (2/702)
The purpose of the study was to ascertain the therapeutic efficacy of different treatments for uncomplicated falciparum malaria in the hospitals in Sagaing, northern and eastern Shan, to facilitate updating the existing national antimalarial drug policy. The proposed 14-day trial for monitoring the efficacy of treatments of uncomplicated falciparum malaria is an efficient method for identifying treatment failure patterns at the intermediate level (township hospital) in the Union of Myanmar. Minimal clinical and parasitological data for days 0-14 were required to classify treatment failure and success. Clinical and parasitiological responses on day 3 and days 4-14 were used as clear examples of early and late treatment failure, respectively. Mefloquine is five times more likely to be effective than chloroquine and sulfadoxine pyrimethamine (S-P), whereas chloroquine and S-P treatments have nearly identical failure patterns. The alarming frequency of clinical and parasitological failure (failure rate > 50%) following chloroquine treatment was reported in Sagaing and following S-P treatment in Sagaing and eastern Shan. (+info)Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. (3/702)
This randomized, open-label clinical trial compared a fixed-dose combination of atovaquone and proguanil (n=55) with chloroquine (n=23) or a combination of chloroquine, sulfadoxine, and pyrimethamine (n=32) for treatment of acute falciparum malaria in the Philippines. Patients were hospitalized for 28 days to ensure medication compliance and prevent reinfection. Atovaquone-proguanil produced a significantly higher cure rate (100%) compared with that for chloroquine (30.4%; P<.0001) or chloroquine-sulfadoxine-pyrimethamine (87.5%; P<.05). Treatments did not differ significantly with respect to parasite clearance time (mean: 46.7 h for atovaquone-proguanil, 60.0 h for chloroquine, and 42.8 h for chloroquine-sulfadoxine-pyrimethamine) or fever clearance time (mean, 38.8, 46.8, and 34.5 h, respectively). Adverse events were typical of malaria symptoms; the most frequently reported events were vomiting (18% for atovaquone-proguanil, 17% for chloroquine, and 9% for chloroquine-sulfadoxine-pyrimethamine), abdominal pain (15%, 17%, and 3%, respectively), anorexia (11%, 13%, and 0%, respectively), and headache (6%, 17%, and 3%, respectively). Atovaquone-proguanil was well tolerated and more effective than chloroquine or chloroquine-sulfadoxine-pyrimethamine for treatment of multidrug-resistant falciparum malaria in the Philippines. (+info)In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia. (4/702)
There is renewed interest in the rich nickel and cobalt deposits of Pulau Gag, an isolated but malarious island off the northwest coast of Irian Jaya. In preparation for an expanded workforce, an environmental assessment of malaria risk was made, focusing upon malaria prevalence in the small indigenous population, and the in vivo sensitivity of Plasmodium falciparum and P. vivax to chloroquine (CQ) and sulfadoxine/pyrimethamine (S/P), the respective first- and second-line drugs for uncomplicated malaria in Indonesia. During April-June 1997, mildly symptomatic or asymptomatic malaria infections were found in 24% of 456 native residents. Infections by P. falciparum accounted for 60% of the cases. Respective day 28 cure rates for CQ (10 mg base/kg on days 0 and 1; 5 mg/kg on day 2) in children and adults were 14% and 55% (P < 0.005). Type RII and RIII resistance characterized only 5% of the CQ failures. Re-treatment of 36 P. falciparum CQ treatment failures with S/P (25 mg/kg and 1.25 mg/kg, respectively) demonstrated rapid clearance and complete sensitivity during the 28-day follow-up period. More than 97% of the P. vivax malaria cases treated with CQ cleared parasitemia within 48 hr. Three cases of P. vivax malaria recurred between days 21 and 28, but against low drug levels in the blood. The low frequency of RII and RIII P. falciparum resistance to CQ, the complete sensitivity of this species to S/P, and the absence of CQ resistance by P. vivax are in contrast to in vivo and in vitro test results from sites on mainland Irian Jaya. (+info)Does the availability of blood slide microscopy for malaria at health centers improve the management of persons with fever in Zambia? (5/702)
Some Ministries of Health in Africa plan to make blood slide microscopy available in peripheral health centers to improve malaria diagnosis over the current practice, which relies solely on clinical findings. To assess whether microscopy improves the management of febrile persons in health centers, we prospectively reviewed medical records of all outpatients visiting six health centers with laboratories in Zambia during a 2-3-day period. Staff interviews and a blinded review of a series of blood slides from each facility by two expert microscopists were also conducted. Of 1,442 outpatients, 655 (45%) reported fevers or had a temperature > or = 37.5 degrees C. Blood slide microscopy was ordered in 28-93% of patients with fever (mean = 46%). Eighty-eight (35%) patients without parasitemia were prescribed an antimalarial drug. Antimalarial drugs were prescribed with equal frequency to those who were referred for a blood slide (56%) and those not referred (58%). The sensitivity of microscopy was 88% and the specificity was 91%. Use of malaria microscopy varied widely, indicating that clinicians are not using standard criteria for ordering this test. Although diagnosis by microscopy was generally accurate, it appeared to have had little impact on the treatment of persons with fever. Guidelines for using blood slide microscopy are needed and prescription of antimalarial drugs should be discouraged when slide results are negative. (+info)Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum. (6/702)
The efficacy and tolerability of single, low-dose mefloquine, sulfadoxine-pyrimethamine (MSP) combination was compared with chloroquine (CQ) for malaria treatment in a malaria-endemic area of Nigeria with multiple drug-resistant Plasmodium falciparum. The two drug regimens (MSP and CQ) were tested in a 12-month prospective population study. The patients were divided into two groups. Group 1 patients were treated presumptively, based on malaria symptoms. Group 2 patients were treated based on a parasitologic diagnosis using the World Health Organization seven-day in vivo test and extended to a 28-day follow-up period. Tolerability was assessed by the incidence and intensity of adverse events. One thousand nine hundred thirty-five patients visiting 10 health facilities, including the University of Calabar Teaching Hospital, were enrolled. The study showed that the low-dose MSP was efficacious, with day 7 response rates of 95% and 91% for (presumptive) Group 1 and (in vivo) Group 2, respectively, while CQ had day 7 response rates of 82% and 66% in Groups 1 and 2, respectively. The low-dose MSP was significantly (P < 0.0001) more efficacious, with faster fever and parasite clearance times than CQ in this area of CQ-resistant P. falciparum malaria. Eight patients treated with CQ, including seven severe cases (RII-RIII) were successfully re-treated with MSP. Adverse events were generally more common among those treated with MSP (29%) than those treated with CQ (17%). However, the adverse events caused by both drugs were mild to moderate and self-limited. The MSP combination appears to be a good substitute for CQ, in view of multiple drug resistance, especially in areas with severe (RII-RIII) malaria. (+info)Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. (7/702)
Resistance to antimalarial chemotherapy is one of the greatest difficulties for the control of malaria transmission. Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy. Resistance levels RI, RII, and RIII were established. Eighteen infections (51%) cleared after chloroquine treatment and did not recur within 28 days of follow-up; these were classified as sensitive. Ten infections (29%) were resistant at the RI level. Resistance at level RII was observed in 5 (14%) cases, and RIII resistance was demonstrated in 2 infections (6%). With sulfadoxine-pyrimethamine, 28 (80%) infections were classified as sensitive. Six infections (17%) showed resistance at level RII, and 1 (3%) infection was resistant at the RI level. Resistance at level RIII was not observed. In a microtest for chloroquine and sulfadoxine-pyrimethamine sensitivity in vitro, schizont development was accomplished successfully in 70 blood samples. In vitro resistance to chloroquine was demonstrated in 15 of 70 (21%) of all isolates. Eight of 70 (11%) of all isolates showed resistance to sulfadoxine-pyrimethamine. Diversity of response of P. falciparum to the studied antimalarial drugs in the Guayana area of Venezuela is considered a problem restricting the control of malaria in this geographical area. A constant evaluation program monitoring P. falciparum drug sensitivity is necessary for preserving the efficacy of the established treatment. (+info)Lack of an association between the ASN-108 mutation in the dihydrofolate reductase gene and in vivo resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum. (8/702)
Sulfadoxine/pyrimethamine (SP) is considered an alternative treatment for acute uncomplicated malaria caused by Plasmodium falciparum resistant to chloroquine. However, the appearance of resistance to this drug has been reported since its initial use in Colombia. Molecular analysis of the dihydrofolate reductase gene indicates a correlation between in vitro resistance to SP and the Asn-108 point mutation. Little is known about the association of this point mutation and in vivo resistance to SP. We used a mutation-specific polymerase chain reaction strategy to analyze the presence of the Asn-108 point mutation in 48 clinical samples with adequate clinical response (ACR), 2 early treatment failures (ETF), and 1 late treatment failure (LTF). The Asn-108 mutation was detected in 36 of the ACR samples and in all of the ETF and LTF samples. Eleven ACR samples amplified with the wild-type-specific primer and one amplified with the primer for the Thr-108 mutation described for resistance to cycloguanil. These results suggest that the Asn-108 marker may not be useful in predicting SP treatment failure. (+info)Sulfadoxine is an antimicrobial drug, specifically a sulfonamide. It is defined in medical terms as a long-acting synthetic antibacterial that is used to treat and prevent various bacterial infections. Sulfadoxine works by inhibiting the growth of bacteria through interfering with their ability to synthesize folic acid, an essential component for their survival.
It is often combined with pyrimethamine (a dihydrofolate reductase inhibitor) to treat and prevent malaria caused by Plasmodium falciparum, particularly in areas where there is resistance to other antimalarial drugs. The combination of sulfadoxine and pyrimethamine is known as a "sulfonamide-pyrimidine" or "SP" treatment.
Sulfadoxine should be used with caution, as it can cause serious side effects such as severe skin reactions, blood disorders, and allergic reactions. It is also not recommended for use in people who have an allergy to sulfonamides or who are breastfeeding infants younger than two months of age.
Sulfanilamides are a group of synthetic antibacterial agents that are chemically related to sulfanilic acid. They work by inhibiting the growth of bacteria, particularly Gram-positive cocci, and have been used in the treatment of various bacterial infections such as pneumonia, meningitis, and urinary tract infections.
Sulfanilamides are absorbed well from the gastrointestinal tract and are distributed widely throughout the body tissues. They are excreted mainly in the urine, and their action is enhanced by acidic urine. Common side effects of sulfonamides include skin rashes, nausea, vomiting, and headache. Rare but serious side effects include blood disorders, liver damage, and Stevens-Johnson syndrome.
Sulfanilamides have been largely replaced by newer antibiotics due to the emergence of drug-resistant bacteria and the availability of safer and more effective alternatives. However, they are still used in some cases, particularly for the treatment of certain parasitic infections and as topical agents for skin infections.
Pyrimethamine is an antiparasitic medication that is primarily used to treat and prevent protozoan infections, such as toxoplasmosis and malaria. It works by inhibiting the dihydrofolate reductase enzyme, which is essential for the parasite's survival. By doing so, it interferes with the synthesis of folate, a vital component for the growth and reproduction of the parasite.
Pyrimethamine is often used in combination with other medications, such as sulfonamides or sulfones, to increase its effectiveness and prevent the development of drug-resistant strains. Common side effects of pyrimethamine include nausea, vomiting, loss of appetite, and headache. It is important to note that pyrimethamine should only be used under the supervision of a healthcare professional due to its potential for serious side effects and interactions with other medications.
Dihydropteroate synthase is a bacterial enzyme that plays a crucial role in the synthesis of folate, an essential nutrient for many organisms, including bacteria. The enzyme catalyzes the reaction between pteridine and para-aminobenzoic acid (pABA) to form dihydropteroate, which is then converted into folate.
Inhibition of this enzyme by drugs such as sulfonamides has been a successful strategy for developing antibiotics that target bacterial folate synthesis while sparing the host's metabolism. This makes dihydropteroate synthase an important target in the development of antimicrobial therapies.
Antimalarials are a class of drugs that are used for the prevention, treatment, and elimination of malaria. They work by targeting the malaria parasite at various stages of its life cycle, particularly the erythrocytic stage when it infects red blood cells. Some commonly prescribed antimalarials include chloroquine, hydroxychloroquine, quinine, mefloquine, and artemisinin-based combinations. These drugs can be used alone or in combination with other antimalarial agents to increase their efficacy and prevent the development of drug resistance. Antimalarials are also being investigated for their potential use in treating other diseases, such as autoimmune disorders and cancer.
A drug combination refers to the use of two or more drugs in combination for the treatment of a single medical condition or disease. The rationale behind using drug combinations is to achieve a therapeutic effect that is superior to that obtained with any single agent alone, through various mechanisms such as:
* Complementary modes of action: When different drugs target different aspects of the disease process, their combined effects may be greater than either drug used alone.
* Synergistic interactions: In some cases, the combination of two or more drugs can result in a greater-than-additive effect, where the total response is greater than the sum of the individual responses to each drug.
* Antagonism of adverse effects: Sometimes, the use of one drug can mitigate the side effects of another, allowing for higher doses or longer durations of therapy.
Examples of drug combinations include:
* Highly active antiretroviral therapy (HAART) for HIV infection, which typically involves a combination of three or more antiretroviral drugs to suppress viral replication and prevent the development of drug resistance.
* Chemotherapy regimens for cancer treatment, where combinations of cytotoxic agents are used to target different stages of the cell cycle and increase the likelihood of tumor cell death.
* Fixed-dose combination products, such as those used in the treatment of hypertension or type 2 diabetes, which combine two or more active ingredients into a single formulation for ease of administration and improved adherence to therapy.
However, it's important to note that drug combinations can also increase the risk of adverse effects, drug-drug interactions, and medication errors. Therefore, careful consideration should be given to the selection of appropriate drugs, dosing regimens, and monitoring parameters when using drug combinations in clinical practice.
Chloroquine is an antimalarial and autoimmune disease drug. It works by increasing the pH or making the environment less acidic in the digestive vacuoles of malaria parasites, which inhibits the polymerization of heme and the formation of hemozoin. This results in the accumulation of toxic levels of heme that are harmful to the parasite. Chloroquine is also used as an anti-inflammatory agent in the treatment of rheumatoid arthritis, discoid or systemic lupus erythematosus, and photodermatitis.
The chemical name for chloroquine is 7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline, and it has a molecular formula of C18H26ClN3. It is available in the form of phosphate or sulfate salts for oral administration as tablets or solution.
Chloroquine was first synthesized in 1934 by Bayer scientists, and it has been widely used since the 1940s as a safe and effective antimalarial drug. However, the emergence of chloroquine-resistant strains of malaria parasites has limited its use in some areas. Chloroquine is also being investigated for its potential therapeutic effects on various viral infections, including COVID-19.
Drug resistance, also known as antimicrobial resistance, is the ability of a microorganism (such as bacteria, viruses, fungi, or parasites) to withstand the effects of a drug that was originally designed to inhibit or kill it. This occurs when the microorganism undergoes genetic changes that allow it to survive in the presence of the drug. As a result, the drug becomes less effective or even completely ineffective at treating infections caused by these resistant organisms.
Drug resistance can develop through various mechanisms, including mutations in the genes responsible for producing the target protein of the drug, alteration of the drug's target site, modification or destruction of the drug by enzymes produced by the microorganism, and active efflux of the drug from the cell.
The emergence and spread of drug-resistant microorganisms pose significant challenges in medical treatment, as they can lead to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antimicrobial agents, as well as poor infection control practices, contribute to the development and dissemination of drug-resistant strains. To address this issue, it is crucial to promote prudent use of antimicrobials, enhance surveillance and monitoring of resistance patterns, invest in research and development of new antimicrobial agents, and strengthen infection prevention and control measures.
'Plasmodium falciparum' is a specific species of protozoan parasite that causes malaria in humans. It is transmitted through the bites of infected female Anopheles mosquitoes and has a complex life cycle involving both human and mosquito hosts.
In the human host, the parasites infect red blood cells, where they multiply and cause damage, leading to symptoms such as fever, chills, anemia, and in severe cases, organ failure and death. 'Plasmodium falciparum' malaria is often more severe and life-threatening than other forms of malaria caused by different Plasmodium species. It is a major public health concern, particularly in tropical and subtropical regions of the world where access to prevention, diagnosis, and treatment remains limited.
Malaria, Falciparum is defined as a severe and often fatal form of malaria caused by the parasite Plasmodium falciparum. It is transmitted to humans through the bites of infected Anopheles mosquitoes. This type of malaria is characterized by high fever, chills, headache, muscle and joint pain, and vomiting. If left untreated, it can cause severe anemia, kidney failure, seizures, coma, and even death. It is a major public health problem in many tropical and subtropical regions of the world, particularly in Africa.
Tetrahydrofolate dehydrogenase (EC 1.5.1.20) is an enzyme involved in folate metabolism. The enzyme catalyzes the oxidation of tetrahydrofolate (THF) to dihydrofolate (DHF), while simultaneously reducing NADP+ to NADPH.
The reaction can be summarized as follows:
THF + NADP+ -> DHF + NADPH + H+
This enzyme plays a crucial role in the synthesis of purines and thymidylate, which are essential components of DNA and RNA. Therefore, any defects or deficiencies in tetrahydrofolate dehydrogenase can lead to various medical conditions, including megaloblastic anemia and neural tube defects during fetal development.
Mefloquine is an antimalarial medication that is used to prevent and treat malaria caused by the Plasmodium falciparum parasite. It works by interfering with the growth of the parasite in the red blood cells of the body. Mefloquine is a synthetic quinoline compound, and it is available under the brand name Lariam, among others.
Mefloquine is typically taken once a week, starting one to two weeks before traveling to an area where malaria is common, and continuing for four weeks after leaving the area. It may also be used to treat acute malaria infection in conjunction with other antimalarial medications.
It's important to note that mefloquine has been associated with serious neuropsychiatric side effects, including anxiety, depression, hallucinations, and seizures. Therefore, it is usually reserved for use in situations where other antimalarial drugs cannot be used or have failed. Before taking mefloquine, individuals should discuss their medical history and potential risks with their healthcare provider.
Dapsone is a medication that belongs to a class of drugs called sulfones. It is primarily used to treat bacterial skin infections such as leprosy and dermatitis herpetiformis (a skin condition associated with coeliac disease). Dapsone works by killing the bacteria responsible for these infections.
In addition, dapsone has anti-inflammatory properties and is sometimes used off-label to manage inflammatory conditions such as vasculitis, bullous pemphigoid, and chronic urticaria. It is available in oral tablet form and topical cream or gel form.
Like all medications, dapsone can cause side effects, which may include nausea, loss of appetite, and headache. More serious side effects, such as methemoglobinemia (a blood disorder that affects the body's ability to transport oxygen), peripheral neuropathy (nerve damage that causes pain, numbness, or weakness in the hands and feet), and liver damage, can occur but are less common.
It is important for patients taking dapsone to be monitored by a healthcare provider to ensure safe and effective use of the medication.
Proguanil is an antimalarial medication that is primarily used to prevent and treat malaria caused by the Plasmodium falciparum parasite. It works by blocking the development of the parasite in the red blood cells, thereby preventing the disease from progressing. Proguanil is often used in combination with other antimalarial drugs such as chloroquine or atovaquone to increase its effectiveness and reduce the risk of drug resistance.
Proguanil is available under various brand names, including Paludrine and Malarona. It is typically taken daily in tablet form, starting before travel to a malaria-endemic area and continuing for several weeks after leaving the area. Proguanil may also be used off-label for other indications, such as treating certain types of cancer or preventing recurrent urinary tract infections. However, its use for these conditions is not well-established and should be discussed with a healthcare provider.
Like all medications, proguanil can have side effects, including nausea, vomiting, diarrhea, headache, and mouth ulcers. It may also interact with other drugs, such as warfarin and metoclopramide, so it is important to inform a healthcare provider of all medications being taken before starting proguanil. Women who are pregnant or breastfeeding should consult their healthcare provider before taking proguanil, as its safety in these populations has not been well-studied.
I'm not aware of any medical definitions associated with the term "Congo." The term "Congo" is most commonly used to refer to:
1. The Congo River, which is the second longest river in Africa, flowing through the Democratic Republic of the Congo and the Republic of the Congo.
2. The two countries located in Central Africa that share the name "Congo": the Democratic Republic of the Congo (formerly known as Zaire) and the Republic of the Congo (formerly known as French Congo or Middle Congo).
3. In historical contexts, "Congo" may also refer to the Congo Free State (1885-1908), a private colony of King Leopold II of Belgium, which later became the Belgian Congo (1908-1960) and then Zaire (1971-1997).
If you are looking for medical information or definitions related to tropical diseases, healthcare in Africa, or similar topics, I would recommend using more specific terms.
Malaria is not a medical definition itself, but it is a disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. Here's a simple definition:
Malaria: A mosquito-borne infectious disease caused by Plasmodium parasites, characterized by cycles of fever, chills, and anemia. It can be fatal if not promptly diagnosed and treated. The five Plasmodium species known to cause malaria in humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.
Sesquiterpenes are a class of terpenes that consist of three isoprene units, hence the name "sesqui-" meaning "one and a half" in Latin. They are composed of 15 carbon atoms and have a wide range of chemical structures and biological activities. Sesquiterpenes can be found in various plants, fungi, and insects, and they play important roles in the defense mechanisms of these organisms. Some sesquiterpenes are also used in traditional medicine and have been studied for their potential therapeutic benefits.
Amodiaquine is an antimalarial medication used to prevent and treat malaria caused by the Plasmodium falciparum parasite. It works by inhibiting the growth of the parasite in red blood cells. Amodiaquine is often used in combination with other antimalarial drugs, such as artesunate or chloroquine.
The chemical name for amodiaquine is 4-[(7-chloro-4-quinolinyl)methyl]-1-(4-amino-1-methylbutyl)piperazine and it has the molecular formula C18H24ClN3O. It is available in the form of tablets for oral administration.
Like all medications, amodiaquine can cause side effects, including nausea, vomiting, loss of appetite, and headache. In rare cases, it can cause more serious side effects such as liver damage, abnormal heart rhythms, and blood disorders. It is important to take amodiaquine exactly as directed by a healthcare provider and to report any unusual symptoms or side effects promptly.
It's important to note that Amodiaquine is not available in all countries and it's use is limited due to the risk of severe side effects, especially when used alone. It should be used only under the supervision of a healthcare provider and with regular monitoring of blood cells, liver function and heart activity.
Folic acid antagonists are a class of medications that work by inhibiting the action of folic acid or its metabolic pathways. These drugs are commonly used in the treatment of various types of cancer and certain other conditions, such as rheumatoid arthritis. They include drugs such as methotrexate, pemetrexed, and trimetrexate.
Folic acid is a type of B vitamin that is essential for the production of DNA and RNA, the genetic material found in cells. Folic acid antagonists work by interfering with the enzyme responsible for converting folic acid into its active form, tetrahydrofolate. This interference prevents the formation of new DNA and RNA, which is necessary for cell division and growth. As a result, these drugs can inhibit the proliferation of rapidly dividing cells, such as cancer cells.
It's important to note that folic acid antagonists can also affect normal, non-cancerous cells in the body, particularly those that divide quickly, such as cells in the bone marrow and digestive tract. This can lead to side effects such as anemia, mouth sores, and diarrhea. Therefore, these drugs must be used carefully and under the close supervision of a healthcare provider.
Artemisinins are a class of antimalarial drugs derived from the sweet wormwood plant (Artemisia annua). They are highly effective against Plasmodium falciparum, the most deadly species of malaria parasite. Artemisinins have become an essential component in the treatment of malaria and are often used in combination therapy regimens to reduce the risk of drug resistance.
The artemisinin compounds contain a unique peroxide bridge that is responsible for their antimalarial activity. They work by generating free radicals that can damage the parasite's membranes, leading to its rapid death. Artemisinins have a fast action and can significantly reduce the parasite biomass in the first few days of treatment.
Some commonly used artemisinin-based combination therapies (ACTs) include:
* Artemether-lumefantrine (Coartem)
* Artesunate-amodiaquine (Coarsucam)
* Artesunate-mefloquine (Artequin)
* Dihydroartemisinin-piperaquine (Eurartesim, Duo-Cotecxin)
Artemisinins have also shown potential in treating other conditions, such as certain types of cancer and viral infections. However, more research is needed to establish their safety and efficacy for these indications.
There doesn't seem to be a specific medical definition for "DNA, protozoan" as it is simply a reference to the DNA found in protozoa. Protozoa are single-celled eukaryotic organisms that can be found in various environments such as soil, water, and the digestive tracts of animals.
Protozoan DNA refers to the genetic material present in these organisms. It is composed of nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which contain the instructions for the development, growth, and reproduction of the protozoan.
The DNA in protozoa, like in other organisms, is made up of two strands of nucleotides that coil together to form a double helix. The four nucleotide bases that make up protozoan DNA are adenine (A), thymine (T), guanine (G), and cytosine (C). These bases pair with each other to form the rungs of the DNA ladder, with A always pairing with T and G always pairing with C.
The genetic information stored in protozoan DNA is encoded in the sequence of these nucleotide bases. This information is used to synthesize proteins, which are essential for the structure and function of the organism's cells. Protozoan DNA also contains other types of genetic material, such as regulatory sequences that control gene expression and repetitive elements with no known function.
Understanding the DNA of protozoa is important for studying their biology, evolution, and pathogenicity. It can help researchers develop new treatments for protozoan diseases and gain insights into the fundamental principles of genetics and cellular function.
4-Aminobenzoic acid, also known as PABA or para-aminobenzoic acid, is an organic compound that is a type of aromatic amino carboxylic acid. It is a white, crystalline powder that is slightly soluble in water and more soluble in alcohol.
4-Aminobenzoic acid is not an essential amino acid for humans, but it is a component of the vitamin folic acid and is found in various foods such as meat, whole grains, and molasses. It has been used as a topical sunscreen due to its ability to absorb ultraviolet (UV) radiation, although its effectiveness as a sunscreen ingredient has been called into question in recent years.
In addition to its use in sunscreens, 4-aminobenzoic acid has been studied for its potential health benefits, including its possible role in protecting against UV-induced skin damage and its potential anti-inflammatory and analgesic effects. However, more research is needed to confirm these potential benefits and to determine the safety and effectiveness of 4-aminobenzoic acid as a dietary supplement or topical treatment.
Parasitic sensitivity tests, also known as parasite drug susceptibility tests, refer to laboratory methods used to determine the effectiveness of specific antiparasitic medications against a particular parasitic infection. These tests help healthcare providers identify which drugs are most likely to be effective in treating an individual's infection and which ones should be avoided due to resistance or increased risk of side effects.
There are several types of parasitic sensitivity tests, including:
1. In vitro susceptibility testing: This involves culturing the parasite in a laboratory setting and exposing it to different concentrations of antiparasitic drugs. The growth or survival of the parasite is then observed and compared to a control group that was not exposed to the drug. This helps identify the minimum inhibitory concentration (MIC) of the drug, which is the lowest concentration required to prevent the growth of the parasite.
2. Molecular testing: This involves analyzing the genetic material of the parasite to detect specific mutations or gene variations that are associated with resistance to certain antiparasitic drugs. This type of testing can be performed using a variety of methods, including polymerase chain reaction (PCR) and DNA sequencing.
3. Phenotypic testing: This involves observing the effects of antiparasitic drugs on the growth or survival of the parasite in a laboratory setting. For example, a parasite may be grown in a culture medium and then exposed to different concentrations of a drug. The growth of the parasite is then monitored over time to determine the drug's effectiveness.
Parasitic sensitivity tests are important for guiding the treatment of many parasitic infections, including malaria, tuberculosis, and leishmaniasis. These tests can help healthcare providers choose the most effective antiparasitic drugs for their patients, reduce the risk of drug resistance, and improve treatment outcomes.
Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.
In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:
1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.
Examples of combination drug therapy include:
1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.
When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.
Parasitemia is a medical term that refers to the presence of parasites, particularly malaria-causing Plasmodium species, in the bloodstream. It is the condition where red blood cells are infected by these parasites, which can lead to various symptoms such as fever, chills, anemia, and organ damage in severe cases. The level of parasitemia is often used to assess the severity of malaria infection and to guide treatment decisions.
"Plasmodium vivax" is a species of protozoan parasite that causes malaria in humans. It's one of the five malaria parasites that can infect humans, with P. falciparum being the most deadly.
P. vivax typically enters the human body through the bite of an infected Anopheles mosquito. Once inside the human host, the parasite travels to the liver where it multiplies and matures. After a period of development that can range from weeks to several months, the mature parasites are released into the bloodstream, where they infect red blood cells and continue to multiply.
The symptoms of P. vivax malaria include fever, chills, headache, muscle and joint pain, and fatigue. One distinctive feature of P. vivax is its ability to form dormant stages (hypnozoites) in the liver, which can reactivate and cause relapses of the disease months or even years after the initial infection.
P. vivax malaria is treatable with medications such as chloroquine, but resistance to this drug has been reported in some parts of the world. Prevention measures include using insecticide-treated bed nets and indoor residual spraying to reduce mosquito populations, as well as taking prophylactic medications for travelers visiting areas where malaria is common.
Genes in protozoa refer to the hereditary units of these single-celled organisms that carry genetic information necessary for their growth, development, and reproduction. These genes are made up of DNA (deoxyribonucleic acid) molecules, which contain sequences of nucleotide bases that code for specific proteins or RNA molecules. Protozoan genes are responsible for various functions, such as metabolism, response to environmental stimuli, and reproduction.
It is important to note that the study of protozoan genes has contributed significantly to our understanding of genetics and evolution, particularly in areas such as molecular biology, cell biology, and genomics. However, there is still much to be learned about the genetic diversity and complexity of these organisms, which continue to be an active area of research.
"Drug evaluation" is a medical term that refers to the systematic process of assessing the pharmacological, therapeutic, and safety profile of a drug or medication. This process typically involves several stages, including preclinical testing in the laboratory, clinical trials in human subjects, and post-marketing surveillance.
The goal of drug evaluation is to determine the efficacy, safety, and optimal dosage range of a drug, as well as any potential interactions with other medications or medical conditions. The evaluation process also includes an assessment of the drug's pharmacokinetics, or how it is absorbed, distributed, metabolized, and eliminated by the body.
The findings from drug evaluations are used to inform regulatory decisions about whether a drug should be approved for use in clinical practice, as well as to provide guidance to healthcare providers about how to use the drug safely and effectively.
I'm sorry for any confusion, but "Kenya" is not a medical term. It is the name of a country located in East Africa, known for its diverse wildlife and geography, including savannas, lakelands, the dramatic Great Rift Valley, and mountain highlands. It is also where you can find the Maasai Mara Reserve, known for its annual wildebeest migrations, and vast Nairobi National Park. The capital city of Kenya is Nairobi. If you have any questions about medical terms or concepts, I would be happy to help with those!
Quinolines are a class of organic compounds that consist of a bicyclic structure made up of a benzene ring fused to a piperidine ring. They have a wide range of applications, but they are perhaps best known for their use in the synthesis of various medications, including antibiotics and antimalarial drugs.
Quinolone antibiotics, such as ciprofloxacin and levofloxacin, work by inhibiting the bacterial enzymes involved in DNA replication and repair. They are commonly used to treat a variety of bacterial infections, including urinary tract infections, pneumonia, and skin infections.
Quinoline-based antimalarial drugs, such as chloroquine and hydroxychloroquine, work by inhibiting the parasite's ability to digest hemoglobin in the red blood cells. They are commonly used to prevent and treat malaria.
It is important to note that quinolines have been associated with serious side effects, including tendinitis and tendon rupture, nerve damage, and abnormal heart rhythms. As with any medication, it is important to use quinolines only under the supervision of a healthcare provider, and to follow their instructions carefully.
I'm sorry for any confusion, but "Tanzania" is not a medical term. It is the name of a country located in East Africa. If you have any questions about medical terms or conditions, I would be happy to help clarify those for you.
I'd be happy to help! However, I believe there might be a slight confusion in your question. RNA stands for Ribonucleic Acid, which is a type of nucleic acid involved in various biological roles in the coding, decoding, regulation, and expression of genes. On the other hand, protozoan refers to a unicellular organism from the kingdom Protista, which includes a wide variety of simple eukaryotic organisms such as amoebas, paramecia, and plasmodium (the malaria-causing parasite).
There isn't a specific medical definition for "RNA, protozoan" since RNA is a molecule present in all living cells, including human cells, and protozoans are a group of organisms. However, I can tell you that RNA plays crucial roles in protozoan biology, such as acting as a messenger between DNA and ribosomes during protein synthesis or regulating gene expression.
If you have any further questions or need more specific information about RNA in protozoans, please let me know!
Treatment failure is a term used in medicine to describe the situation when a prescribed treatment or intervention is not achieving the desired therapeutic goals or objectives. This may occur due to various reasons, such as:
1. Development of drug resistance by the pathogen or disease being treated.
2. Inadequate dosage or frequency of the medication.
3. Poor adherence or compliance to the treatment regimen by the patient.
4. The presence of underlying conditions or comorbidities that may affect the efficacy of the treatment.
5. The severity or progression of the disease despite appropriate treatment.
When treatment failure occurs, healthcare providers may need to reassess the patient's condition and modify the treatment plan accordingly, which may include adjusting the dosage, changing the medication, adding new medications, or considering alternative treatments.
Microbial drug resistance is a significant medical issue that refers to the ability of microorganisms (such as bacteria, viruses, fungi, or parasites) to withstand or survive exposure to drugs or medications designed to kill them or limit their growth. This phenomenon has become a major global health concern, particularly in the context of bacterial infections, where it is also known as antibiotic resistance.
Drug resistance arises due to genetic changes in microorganisms that enable them to modify or bypass the effects of antimicrobial agents. These genetic alterations can be caused by mutations or the acquisition of resistance genes through horizontal gene transfer. The resistant microbes then replicate and multiply, forming populations that are increasingly difficult to eradicate with conventional treatments.
The consequences of drug-resistant infections include increased morbidity, mortality, healthcare costs, and the potential for widespread outbreaks. Factors contributing to the emergence and spread of microbial drug resistance include the overuse or misuse of antimicrobials, poor infection control practices, and inadequate surveillance systems.
To address this challenge, it is crucial to promote prudent antibiotic use, strengthen infection prevention and control measures, develop new antimicrobial agents, and invest in research to better understand the mechanisms underlying drug resistance.
A point mutation is a type of genetic mutation where a single nucleotide base (A, T, C, or G) in DNA is altered, deleted, or substituted with another nucleotide. Point mutations can have various effects on the organism, depending on the location of the mutation and whether it affects the function of any genes. Some point mutations may not have any noticeable effect, while others might lead to changes in the amino acids that make up proteins, potentially causing diseases or altering traits. Point mutations can occur spontaneously due to errors during DNA replication or be inherited from parents.
A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.
An allele is a variant form of a gene that is located at a specific position on a specific chromosome. Alleles are alternative forms of the same gene that arise by mutation and are found at the same locus or position on homologous chromosomes.
Each person typically inherits two copies of each gene, one from each parent. If the two alleles are identical, a person is said to be homozygous for that trait. If the alleles are different, the person is heterozygous.
For example, the ABO blood group system has three alleles, A, B, and O, which determine a person's blood type. If a person inherits two A alleles, they will have type A blood; if they inherit one A and one B allele, they will have type AB blood; if they inherit two B alleles, they will have type B blood; and if they inherit two O alleles, they will have type O blood.
Alleles can also influence traits such as eye color, hair color, height, and other physical characteristics. Some alleles are dominant, meaning that only one copy of the allele is needed to express the trait, while others are recessive, meaning that two copies of the allele are needed to express the trait.
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
Sulfadoxine
Sulfalene
Pyrimethamine
Antimalarial medication
Roche
Quartan fever
Amodiaquine
Malaria
WHO Model List of Essential Medicines
WHO Model List of Essential Medicines for Children
Sydney Grammar School
Intermittent preventive therapy
Artesunate
Mass drug administration
Plasmodium falciparum
Pregnancy-associated malaria
Project 523
Plasmodium vivax
Clerk family
Quinine
Rajpal Singh Yadav
Transient acantholytic dermatosis
Fitness to dive
Plasmodium
Dapsone
Affordable Medicines Facility-malaria
Chemoprophylaxis
Peter Kazembe
ATC code P01
Artemisinin
Sulfadoxine - Wikipedia
EFFECT OF COTRIMOXAZOLE PROPHYLAXIS TAKEN BY HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED PERSONS ON THE SELECTION OF...
Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling...
Sulfadoxine
Malaria Consortium - Resistance markers to sulfadoxine-pyrimethamine and amodiaquine in the context of seasonal malaria...
Drug coverage in treatment of malaria and the consequences for resistance evolution - evidence from the use of sulphadoxine...
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind,...
Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated...
Sulfadoxine-pyrimethamine Archives - PEERSS
Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in...
Association of Genetic Mutations in Plasmodium vivax dhfr with Resistance to Sulfadoxine-Pyrimethamine:...
Buy Sulfadoxine wholesale from the company - 【PharmUp】
Results of search for 'su:{Sulfadoxine.}' › WHO HQ Library catalog
CAS 1262770-70-6 Sulfadoxine-d3 - Analytical Products / Alfa Chemistry
Buy Larinate Kit, Artesunate/ Pyrimethamine/ Sulphadoxine Online
Sulphadoxine Uses & Side effects - Index of Sciences
Sulfadoxine+Pyrimethamine Tablet - Buy Product on Guangzhou Mandison Biotechnology Co.,ltd
Molecular surveillance for anti-malarial drug resistance and genetic diversity of Plasmodium falciparum after chloroquine and...
Updated WHO Policy Recommendation on Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulfadoxine-Pyrimethamine ...
Supply-Raw-Material-CAS-2447-57-6-Sulfadoxine-Powder 副本 | Supopeptide
CDC - Malaria - Glossary
Sulfadoxine-Pyrimethamine IPTp in Malawi: Effects on the gut and vaginal microbiomes - Steven Meshnick
China buy pyrimethamine sulfadoxine manufacturers, buy pyrimethamine sulfadoxine suppliers, buy pyrimethamine sulfadoxine...
Newsletter - Malaria Prevention and Prophylaxis
Buy Sulfadoxine and Pyrimethamine Tablets Online Price from Suppliers & Manufacturers in China | Inopha International Co....
Erythroderma (Generalized Exfoliative Dermatitis): Background, Pathophysiology, Etiology
Malaria32
- Sulfadoxine (also spelled sulphadoxine) is an ultra-long-lasting sulfonamide used in combination with pyrimethamine to treat malaria. (wikipedia.org)
- It is also used to prevent malaria but due to high levels of sulphadoxine-pyrimethamine resistance, this use has become less common. (wikipedia.org)
- Sulfadoxine-resistant Plasmodium falciparum under- mines malaria prevention with sulfadoxine/pyrimethamine. (cdc.gov)
- ABSTRACT A prospective clinical trial was carried out to determine in vivo efficacy of sulfadoxine/py- rimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in children in New Halfa. (who.int)
- In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethaxazole singly and in combination. (ajtmh.org)
- Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. (ajtmh.org)
- Since 2014, seasonal malaria chemoprevention (SMC), using antimalarial medicines sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), has been implemented. (malariaconsortium.org)
- Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. (tropmedres.ac)
- Innovative community strategies to increase intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) coverage is advocated particularly in rural areas, where health infrastructure is weakest and malaria transmission highest. (peerss.org)
- Sulphadoxine works by interfering with the growth and reproduction of the malaria parasite. (indexofsciences.com)
- In addition to its use in treating malaria, sulphadoxine has also been used in the treatment of other infections such as urinary tract infections and respiratory tract infections. (indexofsciences.com)
- Overall, sulphadoxine is an important medication in the fight against malaria, especially in areas where the parasite has developed resistance to other antimalarial drugs. (indexofsciences.com)
- Sulphadoxine is primarily used for the treatment and prevention of malaria, a life-threatening disease caused by the Plasmodium parasite. (indexofsciences.com)
- Sulphadoxine works by inhibiting the synthesis of dihydrofolic acid, which is essential for the survival of the malaria parasite. (indexofsciences.com)
- Sulphadoxine is particularly useful in areas where malaria is prevalent and where the parasite has developed resistance to other antimalarial drugs. (indexofsciences.com)
- Overall, sulphadoxine is an important medication in the fight against malaria and plays a crucial role in preventing and treating this disease. (indexofsciences.com)
- The dosage of sulphadoxine will depend on several factors, including the age, weight, and medical condition of the patient, as well as the severity of the malaria infection being treated. (indexofsciences.com)
- For the treatment of malaria, sulphadoxine is often prescribed in combination with other antimalarial drugs, such as pyrimethamine. (indexofsciences.com)
- For nearly 20 years, pregnant women have been given therapeutic doses of sulfadoxine-pyrimethamine (SP) as intermittent preventive therapy (IPTp) to protect against malaria. (grantome.com)
- Sulfadoxine-Pyrimethamine IPTp in Malawi: Effects on the gut and vaginal microbiomes Narrative Sulfadoxine-pyrimethamine (SP) is widely used among pregnant women as protection against malaria. (grantome.com)
- Sulfadoxine and Pyrimethamine Tablets is a combination medication used to treat malaria typically used along with other antimalarial medication such as artesunate. (inopha.net)
- Sub-microscopic Plasmodium falciparum parasitaemia, dihydropteroate synthase (dhps) resistance mutations to sulfadoxine-pyrimethamine, transmission intensity and risk of malaria infection in pregnancy in Mount Cameroon Region. (bvsalud.org)
- Household use of sulfadoxine pyrimethamine and factors associated with its utilsation in the treatment of childhood malaria in rural Malawi. (mak.ac.ug)
- ABSTRACT Sulfadoxine-pyrimethamine with amodiaquine is recommended by the World Health Organization as seasonal malaria chemoprevention for children aged 3 to 59 months in the sub-Sahel regions of Africa. (ox.ac.uk)
- Primaquine is not recommended for prevention, Metronidazole is used for bacterial and parasitic infections but not malaria, Pyrimethamine is used in combination with sulfadoxine for treatment but not prevention, Chloroquine is not effective against chloroquine-resistant strains, and Quinine is used for treatment but not prevention of malaria. (proprofs.com)
- Resistance to chloroquine and sulfadoxine-pyrimethamine, the cheapest malaria drugs, is becoming more common. (swissinfo.ch)
- Administration of three courses of sulfadoxine/pyrimethamine (SP) as intermittent preventive treatment (IPTi) to infants when they receive EPI vaccines reduced the incidence of malaria and anaemia in infants in an area with low SP resistance, low transmission pressure and high bednet use. (druglib.com)
- C - Risk of P. falciparum malaria, in combination with reported chloroquine and sulfadoxine-pyrimethamine resistance. (tripprep.com)
- Liver and haematological safety of sulfadoxine-pyrimethamine treatment in non-complicated falciparum malaria. (univalle.edu.co)
- Assessment of baseline molecular markers of sulfadoxine-pyrimethamine resistance in Ebonyi and Osun states, Nigeria: Toward implementation of perennial malaria chemoprevention. (malariaconsortium.org)
- Development of resistance to inexpensive treatment drugs such as chloroquine in the 1950s and 1960s and sulphadoxine-pyrimethamine in the 1970s led to the reversal of decades worth of gains achieved by malaria control programs. (cdc.gov)
- The World Health Organization (WHO) since June 1998 has advocated for the use of artemisinin-based combination therapies (ACTs) in countries where Plasmodium falciparum malaria is resistant to traditional antimalarial therapies such as chloroquine, sulfadoxine-pyrimethamine, and amodiaquine (19;22). (bvsalud.org)
Chloroquine and sulfadoxine-pyrimethamine2
- The presence of polymorphisms in genes associated with Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine was evaluated by Sanger sequencing, in 85 P. falciparum day of enrollment samples from a therapeutic efficacy study of artemether-lumefantrine conducted in 2018-2019 in Quibdo, Colombia. (biomedcentral.com)
- It also reviews the way drug resistance develops and spreads, methods used to assess the presence and level of drug resistance, and the extent to which chloroquine and sulfadoxine/pyrimethamine (SP)-the two most widely used antimalarial drugs in the world today-have now lost efficacy. (nationalacademies.org)
Plasmodium3
- RESUME Un essai clinique prospectif a été effectué afin de déterminer l'efficacité in vivo de l'association sulfadoxine-pyriméthamine dans le traitement de l'accès palustre simple à Plasmodium falciparum chez des enfants à New Halfa. (who.int)
- Sélection des gamétocytes mutants de Plasmodium falciparum par une dose curative de sulfadoxine-pyriméthamine à Kollé (Mali) / Abdoul Habib Beavogui. (who.int)
- Plasmodium falciparum resistance to intermittent preventive treatment with sulfadoxine - pyrimethamine (IPTp-SP) continues to spread throughout sub-Saharan Africa . (bvsalud.org)
Artesunate2
- DRC changed its anti-malarial treatment policy to amodiaquine (AQ) and artesunate (AS) in 2005.MethodsThe results of two in vivo efficacy studies, which tested AQ and sulphadoxine-pyrimethamine (SP) monotherapies and AS+SP and AS+AQ combinations in Boende (Equatorial province), and AS+SP, AS+AQ and SP in Kabalo (Katanga province), between 2003 and 2004 are presented. (tropmedres.ac)
- We investigated the efficacy, safety, and tolerability of 2 combinations of artesunate with sulfadoxine-pyrimethamine (SP) in a mesoendemic region in Uganda with SP resistance, from September 1999 to June 2000. (ox.ac.uk)
Amodiaquine1
- of sulfadoxine-pyrimethamine and amodiaquine for three days. (who.int)
Pyrimethamine sulfadoxine5
- Maybe you are a buy pyrimethamine sulfadoxine purchasing manager, who are looking for high quality buy pyrimethamine sulfadoxine , and YanggeBiotech are a professional manufacturer & supplier that can meet your needs. (yanggebiotech.com)
- Not only buy pyrimethamine sulfadoxine we produced have certificated the international industry standard, but we can also meet your customization needs. (yanggebiotech.com)
- We provide online, timely service and you can get professional guidance on buy pyrimethamine sulfadoxine . (yanggebiotech.com)
- Don't hesitate to get in touch with us if you are interested in buy pyrimethamine sulfadoxine , we won't let you down. (yanggebiotech.com)
- Pyrimethamine-sulfadoxine would be an appropriate drug combination to prevent infection in this man. (proprofs.com)
Resistance to sulfadoxine1
- In contrast, mutations in the pfdhps gene were only observed at codon 437, an indication that full resistance to sulfadoxine has not been achieved in Choco. (biomedcentral.com)
Dihydropteroate synthase1
- citation needed] Sulfadoxine competitively inhibits dihydropteroate synthase, interfering with folate synthesis. (wikipedia.org)
Antimalarial drugs2
- We found that human antimalarial drugs (e.g. sulfadiazine, sulfadoxine, pyrimethamine, cycloguanil) were lethal to the model plant Arabidopsis thaliana at similar concentrations to market herbicides glufosinate and glyphosate. (nih.gov)
- Chloroquine, quinine and sulfadoxine/pyrimethamine were the most available and prescribed antimalarial drugs in all 60 pharmacies (government and private) in the city. (who.int)
Preventive1
- Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended to prevent the adverse consequences of MiP. (rti.org)
L'association1
- La chloroquine, la quinine et l'association sulfadoxine-pyriméthamine étaient les antipaludiques les plus disponibles et les plus prescrits dans les 60 pharmacies publiques et privées de la ville. (who.int)
Resistant2
- Spread of sulfadoxine-resistant parasites will intoseparatelineagesbycountry.Thesefindingssupporta compromise the effectiveness of these programs. (cdc.gov)
- Sulfadoxine-Resistant P. falciparum , Eastern Africa infected with parasites that have the A581G mutation in the Tanzanian National Institute for Medical Research, and dhps ( 12 ), which suggests that these parasites manifest the University of North Carolina. (cdc.gov)
Tablets1
- We are China supplier of Sulfadoxine and Pyrimethamine Tablets. (inopha.net)
Inhibits1
- Pyrimethamine is a medication that inhibits the growth of the parasite, while sulfadoxine is an antibiotic that prevents the parasite from reproducing. (proprofs.com)
Regimen2
- Pooled individual patient data from four previously published trials on the pharmacokinetics of sulfadoxine and pyrimethamine in 415 pediatric and 386 adult patients were analyzed using nonlinear mixed-effects modeling to evaluate the current dosing regimen and, if needed, to propose an optimized dosing regimen for children under 5 years of age. (ox.ac.uk)
- An evidence-based dosing regimen was constructed that would achieve sulfadoxine and pyrimethamine exposures in young children and underweight-for-age young children that were similar to those currently seen in a typical adult. (ox.ac.uk)
Africa1
- Sulfadoxine-Pyrimethamine IPTp in Malawi: Effects on the gut and vaginal microbiomes Abstract Adverse birth outcomes, such as low birth weight, are common in sub-Saharan Africa. (grantome.com)
Medication1
- Sulphadoxine is an antimalarial medication that belongs to the class of drugs known as sulfonamides. (indexofsciences.com)
Drug1
- Malawi experienced prolonged use of sulfadoxine/pyrimethamine (SP) as the front-line anti-malarial drug, with early replacement of chloroquine and delayed introduction of artemisinin-based combination therapy. (lstmed.ac.uk)
Patients2
- The dhfr PCR products of P. vivax from 32 Thai patients treated with the antifolate sulfadoxine-pyrimethamine (S-P) were investigated. (ox.ac.uk)
- Under current dosing recommendations, simulation predicted that the median day 7 concentration was below the 25th percentile for a typical adult patient (50 kg) for sulfadoxine for patients in the weight bands of 8 to 9, 19 to 24, 46 to 49, and 74 to 79 kg and for pyrimethamine for patients in the weight bands of 8 to 9, 14 to 24, and 42 to 49 kg. (ox.ac.uk)
Adult1
- The usual adult dose for the combination is one tablet of sulphadoxine 500 mg and pyrimethamine 25 mg, taken once a week for three weeks. (indexofsciences.com)
Infection1
- Sulphadoxine is typically taken orally in tablet form, and the dosage and duration of treatment depend on the severity of the infection and the age and weight of the patient. (indexofsciences.com)
Risk1
- It is important to note that the risk of side effects from sulphadoxine may be higher in people with certain medical conditions, such as liver or kidney disease, as well as in pregnant women and young children. (indexofsciences.com)
Search1
- Results of search for 'su:{Sulfadoxine. (who.int)
Product1
- Combination product containing sulfadoxine 500 mg and 25 mg pyrimethamine. (medscape.com)
Factors1
- Your doctor will consider these factors when determining if sulphadoxine is an appropriate treatment option for you. (indexofsciences.com)
Effects1
- Like all medications, sulphadoxine can cause side effects, although not everyone will experience them. (indexofsciences.com)
Population1
- The population pharmacokinetics of sulfadoxine and pyrimethamine were both best described by a one-compartment disposition model with first-order absorption and elimination. (ox.ac.uk)
Found1
- Underweight-for-age children were found to have 15.3% and 26.7% lower bioavailabilities of sulfadoxine and pyrimethamine, respectively, for each Z-score unit below −2. (ox.ac.uk)